Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

3

Clinical and Pathological Manifestations of Idiopathic Portal Hypertension

Jun Hong Lee, M.D., Dae Hwan Kang, M.D., Chang Hun Lee, M.D.*, Geun Am Song, M.D., Mong Cho, M.D., Ung Suk Yang, M.D.

Clin Mol Hepatol. 2000;6(2):187-196. Published online January 1, 2000

View: 2254 Download: 13

4

A Case of Extrahepatic Portal Vein Thrombosis Treated by Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Young Tak Kim , Hyek Man Kwen , Min Su Kum , Chang Hyeong Lee , Young Oh Kwen , Sung Kook Kim , Yong Hwan Choi , Joon Mo Chung

Clin Mol Hepatol. 1997;3(1):65-69. Published online January 1, 1970

View: 2240 Download: 15

3

The Results of Long - term Follow - up after Transjugular Intrahepatic Portosystemic Shunt for Gastric and Esophageal Bleeding

Young Tak Kim , Hyek Man kwen , Dae Hyun Kim , Min Su Kum , Young Oh Kwen , Sung kook kim , Yong Hwan Choi , Joon Mo Chung , Yong Joo kim

Clin Mol Hepatol. 1996;2(1):37-46.

View: 2347 Download: 12

Snapshot

Examining the therapeutic landscape of beta-blockers in portal hypertension

Anna Brujats, Càndid Villanueva

Received February 24, 2024 Accepted March 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0144 [Epub ahead of print]

View: 1148 Download: 33

Original Article

Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Liu Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi

Received March 22, 2024 Accepted July 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0198 [Accepted]

View: 252 Download: 30

1 | 2 | 3 |

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5413	MAFLD: How is it different from NAFLD?
Viewed By 5222	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5101	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4732	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search